AVELOX 400 MG
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG · DIN 02242965 · BAYER INC
Health Canada status: CANCELLED POST MARKET
What is AVELOX?
AVELOX 400 MG contains MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02242965, held by BAYER INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVELOX used for?
Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated intra-abdominal infections, and complicated skin and skin structure infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242965 |
|---|---|
| Brand name | AVELOX |
| Generic / active ingredient | MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG |
| Manufacturer | BAYER INC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA14 MOXIFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Jul-2019 |
| Original market date | 2000-10-20 00:00:00 |
How is it administered?
400 mg once daily for all indications. Infusion duration for I.V. is 60 minutes. Sequential I.V. to oral therapy is possible.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text summary (refer to full monograph).
How is it supplied?
Not explicitly detailed in the provided text summary, though tablets and 250 mL I.V. bags are mentioned.
Contraindications
Hypersensitivity to moxifloxacin, other fluoroquinolones, or any ingredient in the formulation.
Warnings and precautions
Disabling/persistent adverse reactions (tendonitis, neuropathy, CNS effects); QT prolongation; risk of aortic aneurysm/dissection; exacerbation of myasthenia gravis; fulminant hepatitis.
Is MOXIFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA14 MOXIFLOXACIN. 8 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-MOXIFLOXACIN | 400 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02432242 |
| JAMP-MOXIFLOXACIN | 400 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02443929 |
| M-MOXIFLOXACIN | 400 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02472791 |
| MOXIFLOXACIN | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02520710 |
| MOXIFLOXACIN | 400 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02462974 |
| MOXIFLOXACIN INJECTION | 400 MG / 250 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02433087 |
| SANDOZ MOXIFLOXACIN | 400 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02383381 |
| TEVA-MOXIFLOXACIN | 400 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02375702 |
| AG-MOXIFLOXACIN | 400 MG | TABLET | ANGITA PHARMA INC. | DORMANT | DIN 02478137 |
| APO-MOXIFLOXACIN | 400 MG | TABLET | APOTEX INC | DORMANT | DIN 02404923 |
Who else supplies MOXIFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOXIFLOXACIN appears in 153 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.